Shaji Kumar

93.5k total citations · 12 hit papers
1.0k papers, 35.0k citations indexed

About

Shaji Kumar is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Shaji Kumar has authored 1.0k papers receiving a total of 35.0k indexed citations (citations by other indexed papers that have themselves been cited), including 805 papers in Hematology, 599 papers in Molecular Biology and 395 papers in Oncology. Recurrent topics in Shaji Kumar's work include Multiple Myeloma Research and Treatments (751 papers), Protein Degradation and Inhibitors (288 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (199 papers). Shaji Kumar is often cited by papers focused on Multiple Myeloma Research and Treatments (751 papers), Protein Degradation and Inhibitors (288 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (199 papers). Shaji Kumar collaborates with scholars based in United States, France and Spain. Shaji Kumar's co-authors include S. Vincent Rajkumar, Angela Dispenzieri, Morie A. Gertz, Robert A. Kyle, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, David Dingli, John A. Lust and Philip R. Greipp and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Shaji Kumar

959 papers receiving 34.4k citations

Hit Papers

Improved survival in multiple myeloma and the impact of n... 2007 2026 2013 2019 2007 2013 2017 2009 2012 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Improved survival in multiple myeloma and the impact of novel therapies
    2007 1.7k citations Shaji Kumar, S. Vincent Rajkumar et al. Blood profile →
  2. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
    2013 957 citations Shaji Kumar, Angela Dispenzieri et al. profile →
  3. Multiple myeloma
    2017 755 citations Shaji Kumar, S. Vincent Rajkumar et al. profile →
  4. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
    2009 743 citations Ola Landgren, Robert A. Kyle et al. Blood profile →
  5. Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
    2012 730 citations Shaji Kumar, Angela Dispenzieri et al. Journal of Clinical Oncology profile →
  6. New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
    2012 625 citations Angela Dispenzieri, Morie A. Gertz et al. Journal of Clinical Oncology profile →
  7. Clonal competition with alternating dominance in multiple myeloma
    2012 456 citations Jonathan J. Keats, Marta Chesi et al. Blood profile →
  8. Multiple Myeloma: Diagnosis and Treatment
    2016 453 citations S. Vincent Rajkumar, Shaji Kumar profile →
  9. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
    2018 351 citations Robert A. Kyle, Dirk R. Larson et al. profile →
  10. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
    2020 256 citations Shaji Kumar, Michèle Cavo et al. profile →
  11. Multiple myeloma current treatment algorithms
    2020 211 citations S. Vincent Rajkumar, Shaji Kumar Blood Cancer Journal profile →
  12. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
    2023 168 citations Jeffrey Matous, Surbhi Sidana et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shaji Kumar United States 89 23.4k 22.8k 14.0k 5.7k 2.7k 1.0k 35.0k
Philip R. Greipp United States 85 18.0k 0.8× 17.5k 0.8× 10.9k 0.8× 5.9k 1.0× 2.5k 0.9× 323 28.4k
Philippe Moreau France 89 19.7k 0.8× 17.9k 0.8× 14.4k 1.0× 4.4k 0.8× 3.5k 1.3× 1.0k 32.4k
Martha Q. Lacy United States 78 15.8k 0.7× 16.8k 0.7× 9.4k 0.7× 5.2k 0.9× 1.7k 0.6× 554 25.4k
Rafaël Fonseca United States 84 17.5k 0.8× 16.2k 0.7× 9.9k 0.7× 5.8k 1.0× 1.8k 0.7× 441 25.8k
Angela Dispenzieri United States 106 25.5k 1.1× 31.7k 1.4× 15.6k 1.1× 9.3k 1.6× 2.6k 1.0× 976 47.8k
Bart Barlogie United States 109 30.7k 1.3× 24.5k 1.1× 18.3k 1.3× 5.7k 1.0× 4.0k 1.5× 704 42.4k
Morie A. Gertz United States 102 20.6k 0.9× 30.3k 1.3× 13.6k 1.0× 9.9k 1.7× 2.8k 1.0× 945 44.0k
Paul G. Richardson United States 116 32.3k 1.4× 33.9k 1.5× 22.5k 1.6× 4.6k 0.8× 5.9k 2.2× 1.1k 51.8k
Nikhil C. Munshi United States 106 21.5k 0.9× 25.2k 1.1× 16.7k 1.2× 3.6k 0.6× 6.1k 2.3× 799 40.1k
Evangelos Terpos Greece 77 11.4k 0.5× 8.6k 0.4× 11.7k 0.8× 3.6k 0.6× 1.7k 0.6× 869 23.7k

Countries citing papers authored by Shaji Kumar

Since Specialization
Citations

This map shows the geographic impact of Shaji Kumar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shaji Kumar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shaji Kumar more than expected).

Fields of papers citing papers by Shaji Kumar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shaji Kumar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shaji Kumar. The network helps show where Shaji Kumar may publish in the future.

Co-authorship network of co-authors of Shaji Kumar

This figure shows the co-authorship network connecting the top 25 collaborators of Shaji Kumar. A scholar is included among the top collaborators of Shaji Kumar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shaji Kumar. Shaji Kumar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abdallah, Nadine, Amanika Kumar, Betsy LaPlant, et al.. (2024). Cumulative deficits frailty index and relationship status predict survival in multiple myeloma. Blood Advances. 9(5). 1137–1146. 1 indexed citations
2.
Wellard, Cameron, Elizabeth S. Moore, Bradley Augustson, et al.. (2024). Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry. Blood. 144(Supplement 1). 1951–1951. 1 indexed citations
3.
Zanwar, Saurabh & Shaji Kumar. (2024). Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the future. Leukemia & lymphoma. 66(4). 573–583. 2 indexed citations
4.
Banerjee, Rahul, Aakash Desai, Muhammad Aziz, et al.. (2022). Financial toxicity in hematological malignancies: a systematic review. Blood Cancer Journal. 12(4). 74–74. 33 indexed citations
5.
Façon, Thierry, Jesús F. San Miguel, Meletios Α. Dimopoulos, et al.. (2022). Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. Advances in Therapy. 39(5). 1976–1992. 18 indexed citations
6.
Smadbeck, James B., Neeraj Sharma, Reid G. Meyer, et al.. (2021). Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. Genes Chromosomes and Cancer. 60(10). 678–686. 5 indexed citations
7.
Bansal, Radhika, Sagar Rakshit, & Shaji Kumar. (2021). Extramedullary disease in multiple myeloma. Blood Cancer Journal. 11(9). 161–161. 57 indexed citations
8.
Hwa, Yi L., Martha Q. Lacy, Morie A. Gertz, et al.. (2020). Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal Of Haematology. 106(3). 433–436. 2 indexed citations
9.
Saleh, Abdullah S. Al, M Hasib Sidiqi, Eli Muchtar, et al.. (2019). Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. Biology of Blood and Marrow Transplantation. 25(8). 1520–1525. 7 indexed citations
10.
Lonial, Sagar, Susanna Jacobus, Rafaël Fonseca, et al.. (2019). Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. Journal of Clinical Oncology. 38(11). 1126–1137. 164 indexed citations
11.
Saleh, Abdullah S. Al, M Hasib Sidiqi, Surbhi Sidana, et al.. (2019). Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. American Journal of Hematology. 94(10). 1066–1071. 13 indexed citations
12.
Kapoor, Prashant, Shaji Kumar, Angela Dispenzieri, et al.. (2013). Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology. 31(36). 4529–4535. 120 indexed citations
13.
Keats, Jonathan J., Marta Chesi, Jan B. Egan, et al.. (2012). Clonal competition with alternating dominance in multiple myeloma. Blood. 120(5). 1067–1076. 456 indexed citations breakdown →
14.
Wadhera, Rishi K., Robert A. Kyle, Dirk R. Larson, et al.. (2011). Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood. 118(11). 2985–2987. 29 indexed citations
15.
Kumar, Shaji, Angela Dispenzieri, Jerry A. Katzmann, et al.. (2010). Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 116(24). 5126–5129. 121 indexed citations
16.
Lacy, Martha Q., Suzanne R. Hayman, Morie A. Gertz, et al.. (2009). Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology. 27(30). 5008–5014. 226 indexed citations
17.
Vachon, Celine M., Robert A. Kyle, Terry M. Therneau, et al.. (2009). Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 114(4). 785–790. 87 indexed citations
18.
Landgren, Ola, Robert A. Kyle, Ruth M. Pfeiffer, et al.. (2009). Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 113(22). 5412–5417. 743 indexed citations breakdown →
19.
Chng, Wee Joo, Shaji Kumar, Scott VanWier, et al.. (2007). Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling. Cancer Research. 67(7). 2982–2989. 195 indexed citations
20.
Dispenzieri, Angela, Robert A. Kyle, Jerry A. Katzmann, et al.. (2007). Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 111(2). 785–789. 285 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Philip R. Greipp Breakdown of academic impact, for papers by Philippe Moreau Breakdown of academic impact, for papers by Martha Q. Lacy Breakdown of academic impact, for papers by Rafaël Fonseca Breakdown of academic impact, for papers by Angela Dispenzieri Breakdown of academic impact, for papers by Bart Barlogie Breakdown of academic impact, for papers by Morie A. Gertz Breakdown of academic impact, for papers by Paul G. Richardson Breakdown of academic impact, for papers by Nikhil C. Munshi Breakdown of academic impact, for papers by Evangelos Terpos
Rankless by CCL
2026